Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy

Federico Sottotetti, Barbara Tagliaferri, Gianpiero Rizzo, Raffaella Palumbo, Giulia Chessa, Chiara Raso, Lorenzo Perrone, Alberto Malovini, Valentina Tibollo, Laura Deborah Locati, Paolo Pedrazzoli, Angioletta Lasagna

Article Type

Original Research

Published

This study aims to investigate, through a retrospective approach and in a real-world setting, the activity and effectiveness of CDK4/6i as first-line or second-line treatment in a HR+/HER2-low population compared to matched patients with HR+/HER2-0 disease.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.